Biovie

Yahoo Finance • 5 months ago

Join Biovie’s Exclusive Live Investor Webinar and Q&A Session on December 9

CARSON CITY, Nev., Nov. 19, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, is pleased to inv... Full story

Yahoo Finance • 6 months ago

BIOVIE ALERT: Bragar Eagel & Squire, P.C. is Investigating BioVie Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Bragar Eagel & Squire, P.C. Litigation Partner Brandon Walker Encourages Investors Who Suffered Losses In BioVie (BIVI) To Contact Him Directly To Discuss Their Options If you are a long-term stockholder in BioVie between August 5, 2021 a... Full story

Yahoo Finance • 7 months ago

BioVie to Host Live Investor Webinar and Q&A on Oct. 8

CARSON CITY, Nev., Sept. 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, will host an inv... Full story

Yahoo Finance • 8 months ago

BioVie Highlighted ADDRESS-LC Phase 2 Trial Design Exploring Bezisterim for the Treatment of Neurological Symptoms of Long COVID at Keystone Symposia on Long COVID and Other Post-Acute Infection Syndromes

CARSON CITY, Nev., Aug. 13, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for neurological and neurodegenerative diseases, today announced t... Full story

Yahoo Finance • 8 months ago

Unusual volume stocks in Monday's session

Join us as we delve into today's session and uncover the stocks that are standing out with unusual volume. [unusualvolume] UNUSUAL VOLUME STOCKS TICKER CHANGE COMMENT AUUD [https://www.chartmill.com/stock/quote/AUUD/profile]... Full story

Yahoo Finance • 8 months ago

Top stock movements in today's session.

Intrigued by the market activity one hour before the close of the markets on Friday? Uncover the key winners and losers of today's session in our insightful analysis. [topmovers] TODAY'S TOP GAINERS TICKER CHANGE COMMENT MRM... Full story

Yahoo Finance • 8 months ago

Biovie stock plunges after pricing $12 million public offering

Investing.com -- Biovie Inc (NASDAQ:BIVI) stock plunged 43% after the clinical-stage biopharmaceutical company announced the pricing of a $12 million underwritten public offering. The offering consists of 6 million units priced at $2.00... Full story

Yahoo Finance • 8 months ago

These stocks are moving in today's session

Stay up-to-date with the latest market trends in the middle of the day on Friday. Explore the top gainers and losers during today's session in our detailed report. [topmovers] TOP GAINERS TICKER CHANGE COMMENT SGBX [https://w... Full story

Yahoo Finance • 8 months ago

Traders are paying attention to the gapping stocks in Friday's session.

The session on Friday is off to an intriguing start with several stocks showing significant price gaps. Let's examine the gap up and gap down stocks in today's session. [gap] TOP GAP UP STOCKS TICKER CHANGE COMMENT ORIS [http... Full story

Yahoo Finance • 8 months ago

Which stocks are moving before the opening bell on Friday?

Before the opening bell on Friday, let's take a glimpse of the US markets and explore the top gainers and losers in today's pre-market session. [premarket] TODAY'S PRE-MARKET GAINERS TICKER CHANGE COMMENT ORIS [https://www.ch... Full story

Yahoo Finance • 8 months ago

BioVie stock dips on pricing $12M securities offering

BioVie (NASDAQ:BIVI [https://seekingalpha.com/symbol/BIVI]) has priced [https://seekingalpha.com/pr/20194579-biovie-inc-announces-pricing-of-12-million-public-offering]a public offering of 6 million units at $2.00 per unit, raising approxi... Full story

Yahoo Finance • 8 months ago

BioVie Inc. Announces Pricing of $12 Million Public Offering

CARSON CITY, Nev., Aug. 07, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI, BIVIW), (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies to treat chronic debilitating conditions including liver d... Full story

Yahoo Finance • 9 months ago

BioVie Presented Data Highlighting that Patients Treated with Bezisterim Potentially Experienced an Age Deceleration Advantage Compared to Placebo on 10 Different Biological Clocks at the 2nd World Conference on Aging and Gerontology

CARSON CITY, Nev., July 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders... Full story

Yahoo Finance • 9 months ago

BioVie Appoints Industry Veterans Amy Chappell, MD, FAAN, and Kameel Farag to Board of Directors

CARSON CITY, Nev., July 22, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders... Full story

Yahoo Finance • 10 months ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders ® Congress (A™RD)

CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (BioVie or the Company), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and... Full story

Yahoo Finance • 10 months ago

BioVie Highlights Patient-Centric Design of SUNRISE-PD Trial at Advanced Therapeutics in Movement & Related Disorders® Congress (ATMRD)

CARSON CITY, Nev., June 26, 2025 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders... Full story

Yahoo Finance • 10 months ago

BioVie to Present Overview of Phase 2 SUNRISE-PD Trial at the Advanced Therapeutics in Movement & Related Disorders® Congress

CARSON CITY, Nev., June 24, 2025 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders... Full story

Yahoo Finance • 10 months ago

New to The Street's Show #672 Airs Tonight on Fox Business Network at 10:30 PM EST

Featured as Sponsored Programming: FLOKI, BioVie Inc. (NASDAQ:BIVI), NRX Pharmaceuticals (NASDAQ:NRXP), and Vita Bella NEW YORK CITY, NEW YORK / ACCESS Newswire / June 16, 2025 / New to The Street, a premier financial media platform, anno... Full story

Yahoo Finance • 12 months ago

BioVie Initiates SUNRISE-PD Clinical Trial Assessing Bezisterim in Early Parkinson’s Disease with First Patient Enrolled

SUNRISE-PD evaluating the Company’s anti-inflammatory, insulin-sensitizing candidate bezisterim in patients with Parkinson’s disease who have not been treated with carbidopa/levodopa SUNRISE-PD is one of very few clinical trials for a Par... Full story

Yahoo Finance • last year

ALERT: Grabar Law Office Investigates Claims on Behalf of Shareholders of Axsome Therapeutics, Inc. (NASDAQ: AXSM); BioVie Inc. (NASDAQ: BIVI); Maison Solutions Inc. (NASDAQ: MSS); and Virtu Financial Inc. (NASDAQ: VIRT), as Securities Fraud Class Actions Survive Motions to Dismiss

PHILADELPHIA, April 08, 2025 (GLOBE NEWSWIRE) -- Axsome Therapeutics Inc. (NASDAQ: AXSM) Class Action Survives Motion to Dismiss: Grabar Law Office is investigating claims on behalf of shareholders of Axsome Therapeutics, Inc. (NASDAQ:... Full story